Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines

INTRODUCTION: Dengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9–45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yu-Ching, Sy, Ava Kristy, Jiz, Mario, Tsai, Jih-Jin, Bato, Joan, Quinoñes, Mary Ann, Reyes, Mary Anne Joy, Wang, Wei-Kung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405517/
https://www.ncbi.nlm.nih.gov/pubmed/37554332
http://dx.doi.org/10.3389/fimmu.2023.1202055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405517/
https://www.ncbi.nlm.nih.gov/pubmed/37554332
http://dx.doi.org/10.3389/fimmu.2023.1202055

Ejemplares similares